Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN
Eledon Pharmaceuticals stock price today
$2.6
-1.74
-40.23%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Eledon Pharmaceuticals stock price monthly change
+71.26%
month
Eledon Pharmaceuticals stock price quarterly change
+71.26%
quarter
Eledon Pharmaceuticals stock price yearly change
+144.38%
year
Eledon Pharmaceuticals key metrics
Market Cap | 252.39M |
Enterprise value | N/A |
P/E | -0.47 |
EV/Sales | N/A |
EV/EBITDA | 0.19 |
Price/Sales | N/A |
Price/Book | 0.41 |
PEG ratio | N/A |
EPS | -1.48 |
Revenue | N/A |
EBITDA | -42.38M |
Income | -39.84M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEledon Pharmaceuticals stock price history
Eledon Pharmaceuticals stock forecast
Eledon Pharmaceuticals financial statements
| Jun 2023 | 0 | -9.57M | |
|---|---|---|---|
| Sep 2023 | 0 | -10.34M | |
| Dec 2023 | 0 | -9.62M | |
| Mar 2024 | 0 | -10.29M |
| Dec 2023 | 0 | -9.62M | |
|---|---|---|---|
| Mar 2024 | 0 | -10.29M | |
| Sep 2025 | 0 | -12.29M | |
| Dec 2025 | 0 | -12.59M |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | 0.11% |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 106785000 | 6.83M | 6.4% |
|---|---|---|---|
| Sep 2023 | 96069000 | 4.73M | 4.93% |
| Dec 2023 | 125894000 | 42.47M | 33.74% |
| Mar 2024 | 80818000 | 5.99M | 7.42% |
| Jun 2023 | -8.22M | -30.33M | 33.01M |
|---|---|---|---|
| Sep 2023 | -12.25M | -25.02M | 0 |
| Dec 2023 | -9.13M | 10.07M | 0 |
| Mar 2024 | -8.74M | 9.78M | 1K |
Eledon Pharmaceuticals alternative data
| Aug 2023 | 17 |
|---|---|
| Sep 2023 | 17 |
| Oct 2023 | 17 |
| Nov 2023 | 17 |
| Dec 2023 | 17 |
| Jan 2024 | 17 |
| Feb 2024 | 17 |
| Mar 2024 | 17 |
| Apr 2024 | 17 |
| May 2024 | 20 |
| Jun 2024 | 20 |
| Jul 2024 | 20 |
Eledon Pharmaceuticals other data
3.36%
-39.99%
of ELDN is owned by hedge funds
13
-14
479.29K
-5.70M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 7859378 | 0 |
| Oct 2024 | 4754549 | 0 |
| Quarter | Transcript |
|---|---|
| Q1 2023 12 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 30 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 14 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 11 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Gregory J. Flesher (1970) Consultant | $1,800,000 |
| Dr. Steven N. Perrin Ph.D. (1966) Pres, Chief Scientific Officer & Non Independent Director | $419,390 |
Dr. David-Alexander C. Gros (1972) Chief Executive Officer & Non Independent Director | $242,430 |
-
What's the price of Eledon Pharmaceuticals stock today?
One share of Eledon Pharmaceuticals stock can currently be purchased for approximately $2.6.
-
When is Eledon Pharmaceuticals's next earnings date?
Unfortunately, Eledon Pharmaceuticals's (ELDN) next earnings date is currently unknown.
-
Does Eledon Pharmaceuticals pay dividends?
No, Eledon Pharmaceuticals does not pay dividends.
-
How much money does Eledon Pharmaceuticals make?
Eledon Pharmaceuticals has a market capitalization of 252.39M.
-
What is Eledon Pharmaceuticals's stock symbol?
Eledon Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ELDN".
-
What is Eledon Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Eledon Pharmaceuticals?
Shares of Eledon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Eledon Pharmaceuticals's key executives?
Eledon Pharmaceuticals's management team includes the following people:
- Mr. Gregory J. Flesher Consultant(age: 55, pay: $1,800,000)
- Dr. Steven N. Perrin Ph.D. Pres, Chief Scientific Officer & Non Independent Director(age: 59, pay: $419,390)
- Dr. David-Alexander C. Gros Chief Executive Officer & Non Independent Director(age: 53, pay: $242,430)
-
How many employees does Eledon Pharmaceuticals have?
As Jul 2024, Eledon Pharmaceuticals employs 20 workers, which is 18% more then previous quarter.
-
When Eledon Pharmaceuticals went public?
Eledon Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 17 Sep 2014.
-
What is Eledon Pharmaceuticals's official website?
The official website for Eledon Pharmaceuticals is eledon.com.
-
Where are Eledon Pharmaceuticals's headquarters?
Eledon Pharmaceuticals is headquartered at 19900 MacArthur Boulevard, Irvine, CA.
-
How can i contact Eledon Pharmaceuticals?
Eledon Pharmaceuticals's mailing address is 19900 MacArthur Boulevard, Irvine, CA and company can be reached via phone at +94 92388090.
Eledon Pharmaceuticals company profile:
Eledon Pharmaceuticals, Inc.
eledon.comExchange:
NASDAQ
Full time employees:
20
Industry:
Biotechnology
Sector:
Healthcare
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
19900 MacArthur Boulevard
Irvine, CA 92612
Irvine, CA 92612
CIK: 0001404281
ISIN: US28617K1016
CUSIP: 28617K101
